Dosing time-dependency of the arthritis-inhibiting effect of tacrolimus in mice

Journal of Pharmacological Sciences

Volumn 116, Issue 3, 2011, Pages 264-273

  Obayashi, Kayo ^a   Tomonari, Mari ^b   Yoshimatsu, Hiromichi ^a   Fukuyama, Ryuji ^a   Ieiri, Ichiro ^a   Higuchi, Shun ^a   To, Hideto ^b  

^a KYUSHU UNIVERSITY   (Japan)

^b UNIVERSITY OF TOYAMA   (Japan)

Author keywords

Chronopharmacology; Circadian rhythm; Cytokine; Rheumatoid arthritis; Tacrolimus

Indexed keywords

AMYLOID A PROTEIN; BIOLOGICAL MARKER; INTERLEUKIN 6; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA;

ADVERSE DRUG REACTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD SAMPLING; CHRONOTHERAPY; CIRCADIAN RHYTHM; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG MECHANISM; LEUKOCYTE COUNT; MALE; MOUSE; NEPHROTOXICITY; NONHUMAN; OPTIMAL DRUG DOSE; PLASMA CONCENTRATION-TIME CURVE; PROTEIN BLOOD LEVEL; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SINGLE DRUG DOSE;

EID: 79960418094     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.11029FP     Document Type: Article

References (46)

1. Harris ED Jr. Rheumatoid arthritis. Pathophysiology and implications for therapy. New Engl J Med. 1990;322:1277-1289.
2. Gabriel SE. The epidemiology of rheumatoid arthritis. Rheum Dis Clin North Am. 2001;27:269-281. (Pubitemid 32488705)
3. Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Ann Rev Immunol. 1996;14:397-440. (Pubitemid 26130190)
4. Arend WP. Physiology of cytokine pathways in rheumatoid arthritis. Arthritis Care Res. 2001;45:101-106. (Pubitemid 32280409)
5. McInnes IB, Liew FY. Cytokine networks - towards new therapies for rheumatoid arthritis. Nat Clin Prac Rheumatol. 2005;1: 31-39.
6. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315-324.
7. Kowanko IC, Knapp MS, Pownall R, Swannell AJ. Domiciliary self-measurement in the rheumatoid arthritis and the demonstration of circadian rhythmicity. Ann Rheum Dis. 1982;41:453-455. (Pubitemid 12035488)
8. Bellamy N, Sothern RB, Campbell J, Buchanan WW. Circadian rhythm in pain, stiffness, and manual dexterity in rheumatoid arthritis: relation between discomfort and disability. Ann Rheum Dis. 1991;50:243-248.
9. Bellamy N, Sothern RB, Campbell J, Buchanan WW. Rhythmic variations in pain, stiffness, and manual dexterity in hand osteoarthritis. Ann Rheum Dis. 2002;61:1075-1080. (Pubitemid 35397354)
10. Herold M, Günther R. Circadian rhythm of C-reactive protein in patients with rheumatoid arthritis. Prog Clin Biol Res. 1987; 227B:271-279.
11. Crofford LJ, Kalogeras KT, Mastorakos G, Magiakou MA, Wells J, Kanik KS, et al. Circadian relationships between interleukin (IL)-6 and hypothalamic-pituitary-adrenal axis hormones: failure of IL-6 to cause sustained hypercortisolism in patients with early untreated rheumatoid arthritis. J Clin Endocrinol Metab. 1997; 82:1279-1283. (Pubitemid 27166676)
12. Perry MG, Kirwan JR, Jessop DS, Hunt LP. Overnight variations in cortisol, interleukin 6, tumour necrosis factor α and other cytokines in people with rheumatoid arthritis. Ann Rheum Dis. 2009;68:63-68.
13. Tabuchi M, To H, Sakaguchi H, Goto N, Takeuchi A, Higuchi S, et al. Therapeutic index by combination of adriamycin and docetaxel depends on dosing time in mice. Cancer Res. 2005;65: 8448-8454. (Pubitemid 41330612)
14. To H, Saito T, Ohdo S, Higuchi S, Fujimura A, Kobayashi E. Doxorubicin chronotherapy of in Japanese outpatients with mammary cancer. Drugs in R&D. 2005;6:101-107. (Pubitemid 40485254)
15. Ushijima K, Sakaguchi H, Sato Y, To H, Koyanagi S, Higuchi S, et al. Chronopharmacological study of antidepressants in forced swimming test in mice. J Pharmacol Exp Ther. 2005;315: 764-770. (Pubitemid 41500742)
16. Lightfoot RW Jr. Benoxaprofen administered once a day: determination of optimum dosage schedule. J Rheumatol. 1980; 6 Suppl:61-67.
17. Arvidson NG, Gudbjornsson B, Larsson A, Hallgren R. The timing of glucocorticoid administration in rheumatoid arthritis. Ann Rheum Dis. 1997;56:27-31. (Pubitemid 27060569)
18. Buttgereit F, Doering G, Schaeffler A, Witte S, Sierakowski S, Gromnica-Ihle E, et al. Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (CAPRA-1): a double-blind, randomised controlled trial. Lancet. 2008;371:205-214.
19. To H, Irie S, Tomonari M, WatanabeY, Kitahara T, Sasaki H. Therapeutic index of methotrexate depends on circadian cycling of tumor necrosis factor-α in collagen-induced arthritis rats and mice. J Pharm Pharmacol. 2009;61:1333-1338.
20. To H, Yoshimatsu H, Tomonari M, Ida H, Tsurumoto T, Tsuji Y, et al. Methotrexate chronotherapy is effective against rheumatoid arthritis. Chronobiol Int. 2011;28:267-274.
21. Dumont FJ. FK506, an immunosuppressant targeting calcineurin function. Curr Med Chem. 2000;7:731-748. (Pubitemid 30366639)
22. Miyatake S, Kaminuma O. Inhibitors of NFAT-calcineurin pathway. Nippon Rinsho. 2005;63:1633-1639.
23. Kino T, Hatanaka H, Miyata S, Inamura N, Nishiyama M, Yajima T, et al. FK506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK506 in vitro. J Antibiot. 1987;40:1256-1265. (Pubitemid 17138110)
24. Sakuma S, Kato Y, Nishigaki F, Sasakawa T, Magari K, Miyata S, et al. FK506 potently inhibits T cell activation induced TNF-alpha and IL-1beta production in vitro by human peripheral blood mononuclear cells. Br J Pharmacol. 2000;130:1655-1663. (Pubitemid 30611945)
25. Sakuma S, Kato Y, Nishigaki F, Magari K, Miyata S, Ohkubo Y, et al. Effects of FK506 and other immunosuppressive anti-rheumatic agents on T cell activation mediated IL-6 and IgM production in vitro. Int Immunopharmacol. 2001;1:749-757. (Pubitemid 32206535)
26. Fujimura A, Ebihara A. Administration time-dependent toxicity of a new immunosuppressive agent, tacrolimus (FK 506). Life Sci. 1994;55:485-490. (Pubitemid 24230334)
27. Uchida H, Kobayashi E, Ogino Y, Mizuta K, To H, Okabe R, et al. Chronopharmacology of tacrolimus in rats: toxicity and efficacy in a mouse-to-rat intestinal transplant model and its pharmacokinetic profile. Transplantation Proc. 1999;31:2751-2753.
28. Nandakumar KS, Svensson L, Holmdahl R. Collagen type II-specific monoclonal antibody-induced arthritis in mice: description of the disease and the influence of age, sex and genes. Am J Phathol. 2003;163:1827-1837. (Pubitemid 37310014)
29. Wooley PH, Luthra HS, Krco CJ, Stuart JM, David CS. Type II collagen-induced arthritis in mice. II. Passive transfer and suppression by intravenous injection of anti-type II collagen antibody or free native type II collagen. Arthritis Rheum. 1984;27: 1010-1017.
30. Holmdahl R, Andersson ME, Goldschmidt TJ, Jansson L, Karlsson M, Malmstrom V. Collagen induced arthritis as an experimental model for rheumatoid arthritis. Immunogenetics, pathogenesis and autoimmunity. Acta Pathol Microbiol Immunol Scand. 1989;97:575-584.
31. Abe C, Mitsunaga K, Shiokawa Y. Spontaneous polyarthritis in MRL/l mice. Ryumachi. 1980;20:233-239.
32. Koopman WJ, Gay S. The MRL-lpr/lpr mouse. A model for the study of rheumatoid arthritis. Scand J Rheumatol. 1988;75 Suppl: 284-289.
33. Baumann H, Gauldie J. The acute phase response. Immunol Today. 1994;15:74-80. (Pubitemid 24049800)
34. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. New Engl J Med. 1999;340: 448-454. (Pubitemid 29084777)
35. Magari K, Miyata S, Nishigaki F, Ohkubo Y, Mutoh S, Goto T. Differential effects of FK506 and methotrexate on inflammatory cytokine levels in rat adjuvant-induced arthritis. J Rheumatol. 2003;30:2193-2200. (Pubitemid 37221852)
36. Li S, Lu A, Li B, Wang Y. Circadian rhythms on hypothalamic-pituitary- adrenal axis hormones and cytokines of collagen induced arthritis in rats. J Autoimmun. 2004;22:277-285. (Pubitemid 38543219)
37. Cutolo M, Seriolo B, Craviotto C, Pizzorni C, Sulli A. Circadian rhythms in RA. Ann Rheum Dis. 2003;62:593-596. (Pubitemid 36760552)
38. Yamauchi A, Oishi R, Kataoka Y. Tacrolimus-induced neurotoxicity and nephrotoxicity is ameliorated by administration in the dark phase in rats. Cell Mol Neurobiol. 2004;24:695-704. (Pubitemid 39062431)
39. Fujimura A, Shiga T, Ohashi K, Ebihara A. Chronopharmacokinetic study of a new immunosuppressive agent, FK 506, in mice. Jpn J Pharmacol. 1993;61:137-139. (Pubitemid 23090115)
40. Min DI, Chen HY, Fabrega A, Ukah FO, Wu YM, Corwin C, et al. Circadian variation of tacrolimus disposition in liver allograft recipients. Transplantation. 1996;62:1190-1192.
41. Neidel J, Schulze M, Lindschau J. Association between degree of bone-erosion and synovial fluid-levels of tumor necrosis factor alpha in the knee-joints of patients with rheumatoid arthritis. Inflam Res. 1995;44:217-221.
42. Gál I, Bajnok E, Szántó S, Sarraj B, Glant TT, Mikecz K. Visualization and in situ analysis of leukocyte trafficking into the ankle joint in a systemic murine model of rheumatoid arthritis. Arthritis Rheum. 2005;52:3269-3278. (Pubitemid 41447110)
43. Kaneider NC, Leger AJ, Kuliopulos A. Therapeutic targeting of molecules involved in leukocyte-endothelial cell interactions. FEBS J. 2006;273:4416-4424. (Pubitemid 44401593)
44. Ueki Y, Sagawa A, Tanimura K, Yamada A, Yamamoto K, Tsuda H, et al. A multicenter study of leukocytapheresis in rheumatoid arthritis. Clin Exp Rheumatol. 2007;25:810-816. (Pubitemid 351166430)
45. Abe C, Mitsunaga K, Shiokawa Y. Spontaneous polyarthritis in MRL/l mice. Ryumachi. 1980;20:233-239.
46. Koopman WJ, Gay S. The MRL-lpr/lpr mouse. A model for the study of rheumatoid arthritis. Scand J Rheumatol. 1988;75 Suppl: 284-289.